Clinical Trial

ELEVATE High-Risk PCI Pivotal Study

Study acronym: ELEVATE III
Recruiting
View on ClinicalTrials.gov →
Summary
The ELEVATE III Pivotal Study is a prospective, multi-center, open-label, interventional, randomized, controlled study with an active control group. The study is intended to assess the safety and efficacy of the Elevate™ percutaneous Left Ventricular Assist Device System in patients referred to high-risk percutaneous coronary interventions (HR-PCI).
Protocol Amendment History 1 change
notable Trial sites expanded: 29 -> 33 locations 2026-07-17
Trial Details
NCT Number NCT07001332
Lead Sponsor Magenta Medical Ltd.
Conditions High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Enrollment 290 participants
Start Date 2025-07-25
Primary Completion 2027-03-16 (estimated)
Study Completion 2027-09-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-16